Boston, MA, November 20th, 2015: Biotech Policy Group President Anne Marie Finley will speak at the Genetic Rx Conference at Harvard Medical School on December 3, 2015. Genetic Rx will take place at the Joseph B. Martin Conference Center at Harvard Medical School and will discuss the present and future of genetic therapies, pricing, reimbursement, the regulatory landscape as well as the treatment of patients with rare and ultra-rare genetic diseases.
Ms. Finley will participate in “The Evolving Regulatory Landscape for Genetic Therapies” panel with US and European academics and biotech corporate executives to discuss industry needs for new regulatory paradigms for genetic therapies. “There are a huge number of new genetic therapies in company pipelines. We must work in tandem with the regulatory agencies around the world to ensure an appropriate regulatory framework is in place by the time product applications are submitted so that new therapies can be reviewed without delays. Genetic therapies are often the only hope for patients with both rare and more common diseases. We must do everything we can to ensure waiting patients receive them as rapidly as possible. I am honored to offer my thoughts on solutions to these important questions,” said Finley.
Anne Marie Finley was named a “Top Thought Leader in Orphan Drugs and Rare Diseases last year by the World Orphan Drug Conference.”
Speakers include Jörn Aldag (uniQure), George Church (Harvard Medical School), JC Gutierrez Ramos (Synlogic Therapeutics), Kathy High (Spark Therapeutics), Edward Kaye (Sarepta), Henrik Ørum (Roche), Mene Pangalos (Astrazeneca), Peter Saltonstall (NORD), Akshay Vaishnaw (Alnylam), James Wilson (University of Pennsylvania) among others. Leading investors from Bain Capital, Wellington Management Company, Pioneer Investments, Deerfield Partners, Fidelity Investments, Sofinnova Ventures, and Third Rock Ventures will also be in attendance.
Genetic Rx is sponsored by Alexandria Real Estate Equities, H.C. Wainwright, Alnylam Pharmaceuticals, Agilis Biotherapeutics, Isis Pharmaceuticals, Mintz Levin, Pfizer and the BioPharma Executive Council.
For more information, please visit: http://bbbiotechconference.com/conference-agenda.php?id=35